ABIOMED Inc.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: abiomed.com
Recent Analyst Ratings for ABIOMED Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $235.00 → $380.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/2/2022 | $355.00 → $388.00 | Buy → Hold | Deutsche Bank |
| 10/13/2022 | $300.00 | Buy | Mizuho |
| 4/6/2022 | $330.00 | Peer Perform | Wolfe Research |
| 2/4/2022 | $292.00 → $275.00 | Underweight | Morgan Stanley |
| 2/4/2022 | $345.00 → $325.00 | Market Perform | SVB Leerink |
| 1/7/2022 | $269.00 → $292.00 | Underweight | Morgan Stanley |
| 8/6/2021 | $335.00 → $375.00 | Market Perform | SVB Leerink |
| 7/20/2021 | $355.00 → $335.00 | Market Perform | SVB Leerink |
ABIOMED Inc. Press Releases
Fastest customizable press release news feed in the world
Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the "Offer") to acquire all of the outstanding shares of common stock of Abiomed, Inc. (NASDAQ:ABMD), for an upfront payment of $380.00 per share in cash, plus one non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The Offer, which was previously scheduled to expire at 11:59 p.m., New York City time, on December 13, 2022, has been extende
First Patients in the World Treated with Impella RP Flex with SmartAssist
Abiomed (NASDAQ:ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005137/en/Impella RP Flex with SmartAssist Illustration (Graphic: Business Wire) Impell
Azenta Announces Nomination of Tina S. Nova, Ph.D. and Dorothy E. Puhy to Board of Directors
CHELMSFORD, Mass., Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Tina S. Nova, Ph.D. and Dorothy E. Puhy have been nominated for election to its Board of Directors at the Company's 2023 Annual General Meeting. They will join as non-voting observers of the Company's Board of Directors with immediate effect. "We are fortunate to have candidates of the caliber of Tina and Dorothy for Azenta's Board," said Steve Schwartz, President and CEO. "They will bring tremendous life sciences experience to our Board and are proven value-creators in the space. Their perspectives will be invaluable as Azenta continues to expand and evolve as a leading life sciences company." J
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa
Johnson & Johnson to Acquire Abiomed
Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure
Abiomed (NASDAQ:ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA's highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology designed to optimize patient management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005234/en/Impella RP Flex with SmartAssist (Photo: Business Wire) The Impella RP platform includes the world's smallest percutaneous right heart mechani
Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support Abiomed (NASDAQ:ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. Data from a subgroup analysis of 93 non-Caucasian high-risk PCI patients enrolled in the PROTECT II Randomized Controlled Trial (RCT) finds those who were treated with Abiomed's Impella heart pump had significantly improved clinical outcomes compared to those who were treated with the intra-aortic balloon pump (
ABIOMED Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Abiomed upgraded by Morgan Stanley with a new price target
Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously
Abiomed downgraded by Deutsche Bank with a new price target
Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously
Mizuho initiated coverage on Abiomed with a new price target
Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00
Wolfe Research initiated coverage on Abiomed with a new price target
Wolfe Research initiated coverage of Abiomed with a rating of Peer Perform and set a new price target of $330.00
Morgan Stanley reiterated coverage on Abiomed with a new price target
Morgan Stanley reiterated coverage of Abiomed with a rating of Underweight and set a new price target of $275.00 from $292.00 previously
SVB Leerink reiterated coverage on Abiomed with a new price target
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $325.00 from $345.00 previously
Morgan Stanley reiterated coverage on Abiomed with a new price target
Morgan Stanley reiterated coverage of Abiomed with a rating of Underweight and set a new price target of $292.00 from $269.00 previously
SVB Leerink reiterated coverage on Abiomed with a new price target
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $375.00 from $335.00 previously
SVB Leerink reiterated coverage on Abiomed with a new price target
SVB Leerink reiterated coverage of Abiomed with a rating of Market Perform and set a new price target of $335.00 from $355.00 previously
Deutsche Bank initiated coverage on Abiomed with a new price target
Deutsche Bank initiated coverage of Abiomed with a rating of Buy and set a new price target of $360.00
ABIOMED Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Plano Matthew T. returned 8,406 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Minogue Michael R returned 410,632 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Greenfield Andrew J returned 23,484 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Began Marc A returned 12,237 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Johnson Paula A returned 1,659 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Rivet Jeannine M was granted 9,285 shares
4 - ABIOMED INC (0000815094) (Issuer)
SEC Form 4: Thomas Paul returned 6,357 shares to the company, closing all direct ownership in the company
4 - ABIOMED INC (0000815094) (Issuer)
ABIOMED Inc. SEC Filings
SEC Form 15-12G filed by ABIOMED Inc.
15-12G - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
SEC Form S-8 POS filed by ABIOMED Inc.
S-8 POS - ABIOMED INC (0000815094) (Filer)
ABIOMED Inc. Leadership Updates
Live Leadership Updates
Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson
Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https
Dr. Paula A. Johnson Joins Abiomed Board of Directors
Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae
ABIOMED Inc. Financials
Live finance-specific insights
Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa
Johnson & Johnson to Acquire Abiomed
Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil
Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increase of 10%, or 12% in constant currency, compared to $253 million in the same period of the prior fiscal year. Worldwide product revenue of $264 million, an increase of 10%, or 12% in constant currency, compared to $241 million in the same period of the prior fiscal year. U.S. product revenue of $216 million, an increase of 9% compared to $197 million in the same period of the prior fiscal year due to a 6% increase in patient utilization. Out
Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/551353819 or dial (888) 330-2413 the international number is (240) 789-2721 conference ID 83972. A replay of this conference call will be available until Thursday, August 11, 2022. The replay p
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: Revenue for the quarter totaled $270 million, an increase of 12% compared to $241 million during the same period of the prior fiscal year. In constant currency*, revenue increased 13% compared to the same period of the prior fiscal year. Full year revenue totaled $1.032 billion, compared to $848 million during the same period of the prior fiscal year. Full year revenue increased 22% on a repo
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 660077. A replay of this conference call will be available until Thursday, May 5, 2022. The repl
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 898485. A replay of this conference call will be available until Thursday, February 10, 2022.
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, October 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET October 28, 2021 through
Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients
Abiomed (NASDAQ:ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005259/en/ Annually, more than one million patients are admitted to hospitals in the United States with ADHF. Despite available pharmaceutical treat
ABIOMED Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G filed by ABIOMED Inc.
SC 13G - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G filed by ABIOMED Inc.
SC 13G - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G filed
SC 13G - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - ABIOMED INC (0000815094) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - ABIOMED INC (0000815094) (Subject)